Dicerna Pharma (DRNA) Misses Q2 EPS by 26c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/2/2026

1. REGN
2. CRWD
3. LITE
4. AAPL
5. ABBV
6. MRVL
7. CL
8. ORCL
9. TFII
10. LYB

Go back to Dicerna Pharma (DRNA) Misses Q2 EPS by 26c

Dicerna Reports Second Quarter 2018 Financial and Operating Results and Provides Corporate Update

August 8, 2018 4:05 PM EDT

Management to Host Conference Call Today at 4:30 p.m. ET

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported financial and operating results for the second quarter ended June 30, 2018.

During the second quarter and subsequent period, we took a significant step... More